Print Page     Close Window     

SEC Filings

10-Q
BIOTIME INC filed this Form 10-Q on 08/09/2017
Entire Document
 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
 
Exhibit E

Cell Cure’s Amended Articles
 
THE COMPANIES LAW, 5759-1999

Fourth Amended and Restated Articles of Association of
CELL CURE NEUROSCIENCES LTD.

1.
Name of the company
 
The company’s name in English is: CELL CURE NEUROSCIENCES LTD.
 
2.
Purposes of the company
 
The purposes of the company are to engage in any legally permitted business
 
3.
Registered Share Capital
 
The share capital of the Company is One Hundred Thousand New Israeli Shekels (NIS 100,000), divided into Ten Million (10,000,000) Ordinary Shares of nominal value of One Agora (NIS 0.01) each (the “Ordinary Shares”, or the “Shares”).
 
4.
Shareholder liability
 
The liability of each shareholder for the indebtedness of the Company is limited to payment of the nominal value of the shares held by that shareholder
 
5.
Share transfer, debenture, number of shareholders
 
 
5.1.
The transfer of Shares requires the approval as set forth in Appendix A to these Articles.
 
 
5.2.
Any invitation to the public to subscribe for any shares or debentures or debenture stock of the Company is hereby prohibited.
 
  5.3.
The number of shareholders for the time being of the company (exclusive of persons who are in the employment of the Company and of persons who, having been formerly in the employment of the Company, were, while in such employment, and have continued after such employment to be, shareholders of the Company) is not to exceed fifty (50).
 
  5.4.
Where two (2) or more persons hold one (1) or more share(s) in the company jointly, they shall be deemed to be a single shareholder.
 
6.
All other rights and obligations of the shareholders shall be as set forth in the provisions attached hereto as Appendix A.
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
 
36

© Copyright BioTime, Inc.